

physician portion and submit this completed form

BlueShield. MIRCERA Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the

Patient Information (required)			Provider Information (required)					
Date:			Provider Name:					
Patient Name:			Specialty:		NPI:			
Date of Birth:	Sex: DMale DFemale		Office Phone:		Office Fax:			
Street Address:			Office Street Address:					
City:	State:	Zip:	City:	Stat	te:	Zip:		
Patient ID: R	tient ID:				Physician Signature:			
PHYSICIAN COMPLETES								

Mircera

(methoxy polyethylene glycol-epoetin beta)

**Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit

***Note: Approval cannot be given unless all lab values are provided

NOTE: Form must be completed in its entirety for processing

Is this request for brand or generic? Brand Generic

- 1. Does the patient have a diagnosis of anemia associated with chronic renal failure (CRF) also known as chronic kidney disease (CKD), end stage renal disease (ESRD), or chronic renal insufficiency (CRI)? □Yes □No
- 2. What is the patient's serum ferritin level in nanograms per milliliter (ng/mL)? _____ ng/mL
- 3. Will Micera be used for the treatment of anemia due to cancer chemotherapy? \Box Yes \Box No
- 4. Will Mircera be used in combination with another erythropoiesis stimulating agent (ESA)? □Yes* □No **If YES*, please specify the medication: _____
- 5. Age 3 months-17, please answer the following questions:
 - a Has the patient been on this medication continuously for the last **4 months** excluding samples? \Box Yes \Box No* **If NO*, has the patient's hemoglobin level been stabilized on another erythropoiesis stimulating agent? \Box Yes* \Box No **If YES*, is the patient being converted from their previous erythropoiesis stimulating agent to Mircera? \Box Yes
 - b. What is the patient's hemoglobin level in grams per deciliter (g/dL)? _____ g/dL
 - c. If hemoglobin level is greater than 11 g/dL: Will the dose be held or reduced until the hemoglobin level is less than or equal to 11 g/dL? \Box Yes \Box No
- 6. Age 18 or older, please answer the following question:
 - a. Has the patient been on this medication continuously for the last 4 months excluding samples? Please select answer below:
 - **NO** this is **INITIATION** of therapy, please answer the following questions:
 - i. Is the patient on dialysis? Please select answer below:
 - \Box Yes: What is the patient's hemoglobin level in grams per deciliter (g/dL)? _____ g/dL
 - 1) If hemoglobin level is greater than 11 g/dL: Will the dose be held or reduced until the hemoglobin level is less than or equal to 11 grams per deciliter (g/dL)? □Yes □No

\Box No: What is the patient's hemoglobin level in grams per deciliter (g/dL)? _____ g/dL

1) **If hemoglobin level is greater than 10 g/dL**: Will the dose be held or reduced until the hemoglobin level is less than or equal to 10 grams per deciliter (g/dL)? □Yes □No

YES – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

i. Is the patient on dialysis? Please select answer below:

 \Box Yes: What is the patient's hemoglobin level in grams per deciliter (g/dL)? _____ g/dL

- 1) If hemoglobin level is greater than 11 g/dL: Will the dose be held or reduced until the hemoglobin level is less than or equal to 11 grams per deciliter (g/dL)? □Yes □No
- \Box No: What is the patient's hemoglobin level in grams per deciliter (g/dL)? _____ g/dL
 - 1) **If hemoglobin level is greater than 10 g/dL**: Will the dose be held or reduced until the hemoglobin level is less than or equal to 10 grams per deciliter (g/dL)? □Yes □No



BlueShield. MIRCERA Federal Employee Program. PRIOR APPROVAL REQUEST

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug Prior Authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM- 9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. <u>Please only fax the completed form once as</u> <u>duplicate submissions may delay processing</u> <u>times.</u>



The information provided on this form will be used to determine the provision of healthcare benefits under a U.S. federal government program, and any falsification of records may subject the provider to prosecution, either civilly or criminally, under the False Claim Acts, the False Statements Act, the mail or wire fraud statutes, or other federal or state laws prohibiting such falsification. **Prescriber Certification:** I certify all information provided on this form to be true and correct to the best of my knowledge and belief. I understand that the insurer may request a medical record if the information provided herein is not sufficient to make a benefit determination or requires clarification and I agree to provide any such information to the insurer. Mircera – FEP MD Fax Form Revised 5/31/2024